September 25, 2016 9:28 PM ET

Biotechnology

Company Overview of Syndax Pharmaceuticals, Inc.

Company Overview

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, In...

400 Totten Pond Road

Suite 110

Waltham, MA 02451

United States

Founded in 2005

17 Employees

Phone:

781-419-1400

Fax:

781-419-1420

Key Executives for Syndax Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 56
Total Annual Compensation: $373.4K
President and Chief Operating Officer
Age: 45
Total Annual Compensation: $346.5K
Chief Medical Officer and Senior Vice President
Age: 65
Total Annual Compensation: $140.6K
Compensation as of Fiscal Year 2015.

Syndax Pharmaceuticals, Inc. Key Developments

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) added to S&P Global BMI Index

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) added to S&P Global BMI Index

Syndax Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2016

Syndax Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported license fee revenue of $305,000 compared to $17,000 a year ago. Loss from operations was $8,634,000 compared with $5,542,000 for the same period a year ago. Net loss attributable to common stockholders was $8,358,000 or $0.47 per basic and diluted share compared with $26,338,000 or $440.52 per basic and diluted share for the same period a year ago. The net loss for the three months ended June 30, 2016, included non-cash stock-based compensation expense of $0.8 million related to the issuance of stock option awards to employees and non-employees. For the six months, the company reported license fee revenue of $610,000 compared to $17,000 a year ago. Loss from operations was $17,387,000 compared with $9,976,000 for the same period a year ago. Net loss attributable to common stockholders was $21,286,000 or $1.19 per basic and diluted share compared with $38,410,000 or $649.30 per basic and diluted share for the same period a year ago.

Syndax Pharmaceuticals, Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 08:00 AM

Syndax Pharmaceuticals, Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 08:00 AM. Venue: The Mandarin Oriental Hotel, Boston, Massachusetts, United States. Speakers: Briggs W. Morrison, Chief Executive Officer and Director, Michael A. Metzger, President and Chief Operating Officer.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 6, 2016
UCB Biopharma SPRL, UCB6352
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Syndax Pharmaceuticals, Inc., please visit www.syndax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.